{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:12:45Z","timestamp":1772050365260,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018133","name":"VitreoRetinal Surgery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xops.2025.100796","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T19:27:16Z","timestamp":1744658836000},"page":"100796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oral Antithrombotic Medication Is Associated with Improved Visual Outcomes in Eyes with Submacular Hemorrhage from Wet Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7151-0492","authenticated-orcid":false,"given":"Hemal P.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cason B.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie J.","family":"Karl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lejla","family":"Vajzovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Fekrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.100796_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.survophthal.2015.04.004","article-title":"Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature","volume":"61","author":"Stanescu-Segall","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.xops.2025.100796_bib2","doi-asserted-by":"crossref","first-page":"e1569","DOI":"10.1111\/aos.15137","article-title":"Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry","volume":"100","author":"Gabrielle","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2025.100796_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00006982-199616030-00001","article-title":"Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration","volume":"16","author":"Avery","year":"1996","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100796_bib4","first-page":"179","article-title":"Predisposing factors for atrial fibrillation in the elderly","volume":"14","author":"Wasmer","year":"2017","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.xops.2025.100796_bib5","first-page":"219","article-title":"The relationship between age-related macular degeneration and cardiovascular disease: a meta-analysis","volume":"50","author":"Lee","year":"2021","journal-title":"Iran J Public Health"},{"key":"10.1016\/j.xops.2025.100796_bib6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMcp025373","article-title":"Clinical practice. Care of patients receiving long-term anticoagulant therapy","volume":"349","author":"Schulman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xops.2025.100796_bib7","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/bmj.325.7368.828","article-title":"Bleeding risks of antithrombotic therapy","volume":"325","author":"Fitzmaurice","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.xops.2025.100796_bib8","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.xops.2025.100796_bib9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ajo.2009.08.033","article-title":"Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy","volume":"149","author":"Kuhli-Hattenbach","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100796_bib10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/PL00007887","article-title":"Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration","volume":"238","author":"Tilanus","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2025.100796_bib11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00417-022-05885-2","article-title":"Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration","volume":"261","author":"Weber","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2025.100796_bib12","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0161-6420(86)33540-1","article-title":"Massive hemorrhage complicating age-related macular degeneration. Clinicopathologic correlation and role of anticoagulants","volume":"93","author":"el Baba","year":"1986","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100796_bib13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00347-012-2567-2","article-title":"[Massive subretinal hemorrhage and anticoagulants. An unfortunate combination?]","volume":"109","author":"Kuhli-Hattenbach","year":"2012","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.xops.2025.100796_bib14","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3928\/23258160-20130909-06","article-title":"Association between systemic anticoagulation and rate of intraocular hemorrhage following intravitreal anti-VEGF therapy for age-related macular degeneration","volume":"44","author":"Olson","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.xops.2025.100796_bib15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ophtha.2015.09.046","article-title":"Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Ying","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100796_bib16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/jcm13020367","article-title":"Outcomes in the treatment of subretinal macular hemorrhage secondary to age-related macular degeneration: a systematic review","volume":"13","author":"Confalonieri","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2025.100796_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000534440","article-title":"Current management of subretinal hemorrhage in neovascular age-related macular degeneration","volume":"246","author":"Oncel","year":"2023","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.xops.2025.100796_bib18","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/IAE.0b013e3181e2263c","article-title":"Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration","volume":"30","author":"Fine","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100796_bib19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ophtha.2023.04.014","article-title":"Surgery, tissue plasminogen activator, antiangiogenic agents, and age-related macular degeneration study: a randomized controlled trial for submacular hemorrhage secondary to age-related macular degeneration","volume":"130","author":"Gabrielle","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100796_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.visres.2013.05.004","article-title":"Visual acuity testing. From the laboratory to the clinic","volume":"90","author":"Bailey","year":"2013","journal-title":"Vis Res"},{"key":"10.1016\/j.xops.2025.100796_bib21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/0002-9394(82)90301-4","article-title":"Experimental subretinal hemorrhage in rabbits","volume":"94","author":"Glatt","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100796_bib22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00006982-199616060-00009","article-title":"The use of intravitreal tissue plasminogen activator in the treatment of experimental subretinal hemorrhage in the pig model","volume":"16","author":"Boone","year":"1996","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100796_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00006982-199515040-00009","article-title":"Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage","volume":"15","author":"Coll","year":"1995","journal-title":"Retina"},{"key":"10.1016\/j.xops.2025.100796_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0002-9394(14)72259-7","article-title":"Tissue plasminogen activator treatment of experimental subretinal hemorrhage","volume":"111","author":"Lewis","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100796_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0039-6257(97)00089-1","article-title":"Pathophysiology and management of subretinal hemorrhage","volume":"42","author":"Hochman","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.xops.2025.100796_bib26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archopht.1991.01080050139046","article-title":"Fibrin directs early retinal damage after experimental subretinal hemorrhage","volume":"109","author":"Toth","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.100796_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0950-3536(05)80269-0","article-title":"Plasminogen activators and plasminogen activator inhibitors: biochemical aspects","volume":"8","author":"Rijken","year":"1995","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.xops.2025.100796_bib28","first-page":"28","article-title":"Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement","volume":"119","author":"Handwerger","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.100796_bib29","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/jcm12031035","article-title":"Efficacy evaluation of tissue plasminogen activator with anti-vascular endothelial growth factor drugs for submacular hemorrhage treatment: a meta-analysis","volume":"12","author":"He","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.xops.2025.100796_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.thromres.2010.09.008","article-title":"The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants","volume":"127","author":"Samama","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.xops.2025.100796_bib31","series-title":"Warfarin","author":"Patel","year":"2024"},{"issue":"2 Suppl","key":"10.1016\/j.xops.2025.100796_bib32","doi-asserted-by":"crossref","first-page":"e89S","DOI":"10.1378\/chest.11-2293","article-title":"Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Eikelboom","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.xops.2025.100796_bib33","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3390\/biom13071124","article-title":"Effects of antiplatelet drugs on platelet-dependent coagulation reactions","volume":"13","author":"Muravlev","year":"2023","journal-title":"Biomolecules"}],"updated-by":[{"DOI":"10.1016\/j.xops.2025.100976","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000}},{"DOI":"10.1016\/j.xops.2025.100976","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000}}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:43:41Z","timestamp":1772048621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914525000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666914525000946"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.100796","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Antithrombotic Medication Is Associated with Improved Visual Outcomes in Eyes with Submacular Hemorrhage from Wet Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.100796","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100796"}}